Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4302814 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| LY4302814 IV | EXPERIMENTAL | LY4302814 administered intravenously (IV) |
| Placebo IV | PLACEBO_COMPARATOR | Placebo administered IV |
| LY4302814 SC | EXPERIMENTAL | LY4302814 administered subcutaneously (SC) |
| Placebo SC | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY4302814 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation. * Have clinical laboratory test results within the normal range for the population or investigative site or with abnormalities deemed not clinically significant by the investigator. * Have a body weight of 45 kilograms (...
LY4302814 is an investigational small molecule drug being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single recruiting trial evaluating it in healthy participants. The specific disease or condition it is intended to treat has not been disclosed.
LY4302814 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the ongoing Phase 1 study of the compound in healthy volunteers.
LY4302814 is in Phase 1 clinical development. It has one active, recruiting Phase 1 trial and no completed trials. Because it is still investigational, it has not been approved by the FDA for any indication.
LY4302814 is being studied in one Phase 1 trial, NCT07566338, titled A Study of LY4302814 in Healthy Participants. The trial is recruiting, is placebo-controlled, randomized, and double-blind, and plans to enroll 150 healthy volunteers aged 18 and older in the United States and Singapore.
Yes. The single Phase 1 trial of LY4302814, NCT07566338, enrolls healthy volunteers rather than patients with a specific disease. It is a randomized, double-blind, placebo-controlled study with an planned enrollment of 150 participants across sites in the United States and Singapore.